New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology.
Xingyu ZhouDong XuMeng Tao LiXiao-Feng ZengPublished in: Expert opinion on investigational drugs (2024)
Unlinked pathobiology with symptoms resulted in misidentified targets and disappointing trials. Useful stratification tools are necessary for the heterogeneous SS patients. Composite endpoints or improvements in ESSDAI scores are needed, considering the high placebo response, and the unbalance between symptom burden and disease activity. Compared to classic biologics, targeted cell therapy will be a more promising field of investigation in the coming years.
Keyphrases
- cell therapy
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- end stage renal disease
- rheumatoid arthritis patients
- ankylosing spondylitis
- ejection fraction
- newly diagnosed
- chronic kidney disease
- stem cells
- mesenchymal stem cells
- juvenile idiopathic arthritis
- patient reported
- peritoneal dialysis
- patient reported outcomes
- physical activity
- cancer therapy
- open label
- double blind